Starling Oncology Institute (STLN) Stock Statistics & Valuation Metrics

Starling Oncology Institute has a market cap or net worth of $695.88M. The enterprise value is $622.84.

Starling Oncology Institute has 99,982,930 shares outstanding. The number of shares has decreased by -2.65% in one year.

Starling Oncology Institute’s return on equity (ROE) is 3.86 and return on invested capital (ROIC) is -35.70%.

The current PE Ratio of Starling Oncology Institute is ―. Starling Oncology Institute’s PEG ratio is 0.00.

In the last 12 months, Starling Oncology Institute had revenue of 502.73M and earned -60.61M in profits. Earnings per share was -0.54.

In the last 12 months, operating cash flow was 328.00K and capital expenditures -3.61M, giving a free cash flow of -3.29M billion.

Starling Oncology Institute pays an annual dividend of ―, resulting in a dividend yield of ―

Starling Oncology Institute upcoming earnings date is Nov 11, 2026, After Close (Confirmed).

Starling Oncology Institute as a current ratio of 1.59, with Debt / Equity ratio of -419.35%

In the past 12 months, Starling Oncology Institute has paid -131.00K in taxes.

Starling Oncology Institute EV to EBITDA ratio is -14.25, with an EV/FCF ratio of -21.81.

Starling Oncology Institute has $41.09M in cash and marketable securities with $104.48M in debt, giving a net cash position of -$63.38M billion.

Gross margin is 15.69%, with operating margin of -7.18%, and net profit margin of -12.06%.

The average price target for Starling Oncology Institute is $9.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy